A review of effects of atorvastatin in cancer therapy

Shaghaghi, Zahra; Alvandi, Maryam; Farzipour, Soghra; Dehbanpour, Mohammad Reza; Nosrati, Sahar

doi:10.1007/s12032-022-01892-9

Cited by 12 publications

(5 citation statements)

References 196 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Atorvastatin is a third-generation synthetic HMG-CoA reductase inhibitor. It was shown that atorvastatin is more efficient in reducing low-density (LDL), very low-density lipoproteins (VLDL), and triglycerides compared to other statins [ 64 , 65 ]. The half-life of atorvastatin is 20 h, which is 5–10 times longer than other HMG-CoA reductase inhibitors [ 66 ].…”

Section: Discussionmentioning

confidence: 99%

Atorvastatin Can Modulate DNA Damage Repair in Endothelial Cells Exposed to Mitomycin C

Sinitsky

Asanov

Цепокина

et al. 2023

IJMS

View full text Add to dashboard Cite

HMG-CoA reductase inhibitors (statins) are widely used in the therapy of atherosclerosis and have a number of pleiotropic effects, including DNA repair regulation. We studied the cytogenetic damage and the expression of DNA repair genes (DDB1, ERCC4, and ERCC5) in human coronary artery (HCAEC) and internal thoracic artery endothelial cells (HITAEC) in vitro exposed to mitomycin C (MMC) (positive control), MMC and atorvastatin (MMC+Atv), MMC followed by atorvastatin treatment (MMC/Atv) and 0.9% NaCl (negative control). MMC/Atv treated HCAEC were characterized by significantly decreased micronuclei (MN) frequency compared to the MMC+Atv group and increased nucleoplasmic bridges (NPBs) frequency compared to both MMC+Atv treated cells and positive control; DDB1, ERCC4, and ERCC5 genes were upregulated in MMC+Atv and MMC/Atv treated HCAEC in comparison with the positive control. MMC+Atv treated HITAEC were characterized by reduced MN frequency compared to positive control and decreased NPBs frequency in comparison with both the positive control and MMC/Atv group. Nuclear buds (NBUDs) frequency was significantly lower in MMC/Atv treated cells than in the positive control. The DDB1 gene was downregulated in the MMC+Atv group compared to the positive control, and the ERCC5 gene was upregulated in MMC/Atv group compared to both the positive control and MMC+Atv group. We propose that atorvastatin can modulate the DNA damage repair response in primary human endothelial cells exposed to MMC in a cell line- and incubation scheme-dependent manner that can be extremely important for understanding the fundamental aspects of pleoitropic action of atorvastatin and can also be used to correct the therapy of patients with atherosclerosis characterized by a high genotoxic load.

show abstract

Section: Discussionmentioning

confidence: 99%

Atorvastatin Can Modulate DNA Damage Repair in Endothelial Cells Exposed to Mitomycin C

Sinitsky

Asanov

Цепокина

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Many existing studies have confirmed that atorvastatin can effectively control and reduce the level of low-density lipoprotein cholesterol [28,29] , which has important value in systolic heart failure, atherosclerosis and controlling the progression of sclerotic plaque lesions. At present, the academic community believes that atorvastatin has a significant effect on regulating high and low density lipoprotein cholesterol levels in patients with coronary heart disease and angina pectoris, and can affect important indicators such as lactate dehydrogenase, creatinase isoenzyme and hydroxybutyrate dehydrogenase phosphate levels.…”

Section: Treatment Of Coronary Heart Disease and Angina Pectorismentioning

confidence: 97%

Analysis of the Effects of Betahistine Hydrochloride Combined with Atorvastatin on Procalcitonin and C-Reactive Protein Levels in Acute Cerebrovascular Disease

Sun,

Pan,

Wang

et al. 2023

IJPS

View full text Add to dashboard Cite

Effects of Betahistine Hydrochloride Combined with Atorvastatin in Acute Cerebrovascular DiseaseAcute cerebrovascular diseases are a group of common clinical diseases characterized by abnormal cerebrovascular circulation. Among many common and frequently occurring diseases admitted to emergency and critical care departments, the mortality rate is high and the disability rate of surviving patients is also high. In addition to central injury in acute cerebrovascular diseases, which can lead to poor prognosis in patients, fluctuations in the properties and functions of local and circulating immune mediators can also trigger the body to enter an immune imbalance state, leading to poor prognosis in some patients after receiving systematic symptomatic support treatment. Betahistine hydrochloride is a histamine H 1 receptor agonist that can resist platelet aggregation. The drug has a half-life of 5 h through liver metabolism and will not remain in the body, resulting in high safety. In addition, betahistine hydrochloride also has a diuretic effect, which can promote blood circulation, increase organ blood perfusion, reduce myocardial oxygen consumption, improve patient blood pressure levels and ultimately improve symptoms of cardiovascular and cerebrovascular ischemia and hypoxia. Therefore, this article mainly reviews the treatment of acute cerebrovascular disease with betahistine hydrochloride combined with atorvastatin, providing scientific reference for clinical treatment of acute cerebrovascular disease.

show abstract

“…Several other promising examples of positioning non-oncology drugs in the treatment of cancer have been reported, including itraconazole, statins [ 85 ], metformin, aspirin, digoxin, and pantoprazole. Itraconazole is a potent anti-fungal drug that inhibits lanosterol-14α-demethylase in the cell membrane of the fungus [ 86 ].…”

Section: Current Applications Of the Hd 3 Approachmentioning

confidence: 99%

Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)

Jackson¹,

Racz

Kim

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

In an era of unparalleled technical advancement, the pharmaceutical industry is struggling to transform data into increased research and development efficiency, and, as a corollary, new drugs for patients. Here, we briefly review some of the commonly discussed issues around this counterintuitive innovation crisis. Looking at both industry- and science-related factors, we posit that traditional preclinical research is front-loading the development pipeline with data and drug candidates that are unlikely to succeed in patients. Applying a first principles analysis, we highlight the critical culprits and provide suggestions as to how these issues can be rectified through the pursuit of a Human Data-driven Discovery (HD3) paradigm. Consistent with other examples of disruptive innovation, we propose that new levels of success are not dependent on new inventions, but rather on the strategic integration of existing data and technology assets. In support of these suggestions, we highlight the power of HD3, through recently published proof-of-concept applications in the areas of drug safety analysis and prediction, drug repositioning, the rational design of combination therapies and the global response to the COVID-19 pandemic. We conclude that innovators must play a key role in expediting the path to a largely human-focused, systems-based approach to drug discovery and research.

show abstract

A review of effects of atorvastatin in cancer therapy

Cited by 12 publications

References 196 publications

Atorvastatin Can Modulate DNA Damage Repair in Endothelial Cells Exposed to Mitomycin C

Atorvastatin Can Modulate DNA Damage Repair in Endothelial Cells Exposed to Mitomycin C

Analysis of the Effects of Betahistine Hydrochloride Combined with Atorvastatin on Procalcitonin and C-Reactive Protein Levels in Acute Cerebrovascular Disease

Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)

Contact Info

Product

Resources

About